Smith, Kline & French

From WikiMD's WELLNESSPEDIA

Smith, Kline & French (SKF) was an American pharmaceutical company, known for its innovative contributions to the healthcare industry. It was founded in 1830 by Mahlon Kline and John K. Smith in Philadelphia, Pennsylvania. The company was later acquired by GlaxoSmithKline in 2000.

History[edit]

SKF was established in 1830 by Mahlon Kline and John K. Smith as a drugstore in Philadelphia. The company initially focused on the production of drugs and pharmaceuticals. In 1865, the company was incorporated as Smith, Kline & Co. and expanded its operations to include the manufacturing of pharmaceuticals.

In 1891, the company merged with French, Richards & Co., becoming Smith, Kline & French. The company continued to grow and innovate, introducing products such as Thorazine (chlorpromazine), the first widely used antipsychotic, and Dexedrine (dextroamphetamine), a stimulant used to treat ADHD and narcolepsy.

In 1989, Smith, Kline & French merged with Beecham Group, a British pharmaceutical company, to form SmithKline Beecham. The merger was one of the largest in the pharmaceutical industry at the time. In 2000, SmithKline Beecham merged with Glaxo Wellcome to form GlaxoSmithKline, one of the world's leading pharmaceutical companies.

Contributions to Healthcare[edit]

Smith, Kline & French made significant contributions to the healthcare industry. The company was known for its innovative research and development. It introduced several groundbreaking drugs, including Thorazine and Dexedrine, which had a significant impact on the treatment of mental health disorders and attention deficit hyperactivity disorder (ADHD), respectively.

Legacy[edit]

Today, the legacy of Smith, Kline & French lives on in GlaxoSmithKline. The company continues to be a leader in the pharmaceutical industry, with a strong commitment to research and development, and a broad portfolio of innovative medicines.

See Also[edit]

Stub icon

This pharmacology-related article is a stub. You can help WikiMD by expanding the page.

  • SmithKline & French Logo
    SmithKline & French Logo

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Smith,_Kline_%26_French&oldid=6347681"